

ESCOBAR - URIBE ASOCIADOS

A B O G A D O S

Carrera 11A No. 94-76 Of. 305 - P.O. Box 94948, Bogotá, Colombia, S.A.

Tel.: (571) 6162051 - 6162061 - 6161000 - 6161001

Fax: (571) 6161885

SUPERINDUSTRIA Y COMERCIO

Radicación : 01109552 00000001

Folios: 42

Fecha (AMB): 2002-02-07 16:18:40

Trámite : 002 PATENTES D 1 REGISTRO/ 329 COMPLEMEN

Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

2462/P

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO DIVISIÓN DE NUEVAS CREACIONES

E. S. D.

Re: Expediente No. 01.109.552
Solicitud de Patente en nombre de
McNeil-PPC, Inc.

Yo, JIMENA ESCOBAR URIBE, identificada como aparece al pie de mi firma, domiciliada en Bogotá, en la Carrera 11 A No. 94-76 Of. 305, obrando como apoderada de la sociedad McNeil-PPC, Inc., solicitante de la patente de la referencia, anexo al presente memorial los siguientes documentos:

Copia certificada de la solicitud de Patente Número 09/745,243 ✓
presentada en los Estados Unidos de América el día 21 de diciembre de 2000, con la debida traducción de lo pertinente, incluyendo el capítulo reivindicatorio.

A este mismo respecto, debe tenerse en cuenta que en la primera página de la copia en mención la Oficina de Patentes correspondiente certificó la fecha de presentación de esa solicitud, cumpliéndose de esta forma todos y cada uno de los requisitos establecidos en el inciso segundo del artículo 10 de la Decisión 486 de la Comisión de la Comunidad Andina.

Señor Superintendente,


JIMENA ESCOBAR URIBE
C.C.39.779.452 de usaquén
T.P. 68228

52

**ESTADOS UNIDOS DE AMERICA
A TODOS AQUELLOS A QUIENES EL PRESENTE
LLEGUE:**

**DEPARTAMENTO DE COMERCIO DE LOS ESTADOS
UNIDOS
Oficina de Patentes y Marcas de los Estados Unidos**

Febrero 1, 2002

La presente es para certificar que el anexo es una copia fiel de los registros de la Oficina de Patentes y Marcas de los Estados Unidos, de los documentos de la solicitud de patente identificada más adelante, que cumplieron con los requerimientos para concederse una fecha de presentación de acuerdo con 35 USC 111.

Número de Solicitud: 09/745,243

Fecha de Presentación: Diciembre 21, 2000

Por la autoridad del
Comisionado de Patentes y Marca

(fdo) L. EDELEN
Oficial Certificador
Sello oficial de la Oficina de Patentes y Marcas de los
Estados Unidos de América

53

REIVINDICACIONES

- 1.- Una partícula de textura encubierta comprende: a) un núcleo que contiene un ingrediente activo; b) una primera capa de revestimiento comprendida de un agente de encubrimiento de sabor que cubre substancialmente el núcleo; y c) una segunda capa de revestimiento en la superficie de la primera capa de revestimiento, la segunda capa de revestimiento está comprendida de: i) un polímero formador de película; ii) un agente antigranuloso.
- 2.- La partícula de conformidad con la reivindicación 1, caracterizada además porque la segunda capa de revestimiento cubre sustancialmente la primera capa de revestimiento.
- 3.- La partícula de conformidad con la reivindicación 1, caracterizada además porque el ingrediente activo se selecciona del grupo que consiste en un fármaco antiinflamatorio no esteroideo, acetaminofeno, pseudoefedrina, meclizina, famotidina, loperamida, ranitidina, cimetidina, astemizol, loratadina, desloratadina, fexofenadina, cetirizina, antácidos, sales farmacéuticamente aceptables de los mismos, metabolitos de los mismos, y mezclas de los mismos.
- 4.- La partícula de conformidad con la reivindicación 1, caracterizada además porque el agente de encubrimiento de sabor se comprende de una mezcla de a) un polímero entérico, y b) un polímero formador de película insoluble.
- 5.- La partícula de conformidad con la reivindicación 4, caracterizada además porque el polímero entérico se selecciona del grupo que consiste en ftalato de hidroxipropilmetilcelulosa, acetato succinato de hidroxipropilmetilcelulosa, acetato ftalato de celulosa, y mezclas de los mismos.
- 6.- La partícula de conformidad con la reivindicación 4, caracterizada además porque el polímero formador de película insoluble se selecciona del grupo que consiste en acetato de celulosa, etilcelulosa, y mezclas de los mismos.
- 7.- La partícula de conformidad con la reivindicación 4, caracterizada además porque la relación en peso del polímero entérico a polímero formador de película insoluble en la primera capa de revestimiento se encuentra en la escala de alrededor de 20:80 a aproximadamente 80:20.

- 8.- La partícula de conformidad con la reivindicación 1, que cumple con la especificación de disolución de USP para formas de dosificación de liberación inmediata que contienen el ingrediente activo particular.
- 9.- La partícula de conformidad con la reivindicación 1, caracterizada además porque el polímero formador de película se selecciona de grupo que consiste en hidroxipropilmetilcelulosa, hidroxipropilcelulosa, hidroxietilcelulosa, y carboximetilcelulosa de sodio, almidones, alginatos, alcoholes polivinílicos, gomas xantano, gomas guar, polisacáridos, pectinas, gelatinas y mezclas de los mismos.
- 10.- La partícula de conformidad con la reivindicación 1, caracterizada además porque el agente antigranuloso se selecciona del grupo que consiste en óxido de polietileno, polietilenglicol y mezclas de los mismos.
- 11.- La partícula de conformidad con la reivindicación 1, caracterizada además porque la segunda capa de revestimiento consta de una mezcla de hidroxipropilmetilcelulosa y polietilenglicol.
- 12.- La partícula de conformidad con la reivindicación 1, caracterizada además porque la relación en peso de la película que forma el polímero a agente antigranuloso en la segunda capa de revestimiento está en la escala de aproximadamente 10:9 a alrededor de 90:10.
- 13.- La partícula de conformidad con la reivindicación 1, caracterizada además porque la relación en peso de polímero formador de película a agente antigranuloso en la segunda capa de revestimiento está en la escala de aproximadamente 50:50.
- 14.- Una tableta que consta de las partículas que se reclaman en la reivindicación 1.
- 15.- Una tableta masticable que consta de las partículas que se reclaman en la reivindicación 1.
- 16.- La tableta masticable de conformidad con la reivindicación 15, caracterizada además porque la primera capa de revestimiento carece sustancialmente de plastificador.
- 17.- La tableta masticable de conformidad con la reivindicación 15, caracterizada además porque el ingrediente activo es un fármaco antiinflamatorio no esteroideo, acetaminofen pseudoefedrina, fenilpropanolamina, clorfeniramina, dextrometorfan, difenhidramina, dimenhidrinato, meclizina, famotidina, loperamida, ranitidina, cimetidina,

5

astemizol, loratadina, desloratadina, fexofenadina, cetirizina, antiácidos, sales farmacéuticamente aceptables de los mismos, sus metabolitos y sus mezclas.

- 18.- La tableta masticable de conformidad con la reivindicación 15, caracterizada además porque cumple con la especificación de disolución de la USP para tabletas masticables de liberación inmediata que contienen el ingrediente activo particular.
- 19.- La tableta masticable de conformidad con la reivindicación 15, caracterizada además porque el polímero formador de película se selecciona del grupo que consiste en hidroxipropilmetilcelulosa, hidroxipropilcelulosa, hidroxietilcelulosa y carboximetilcelulosa de sodio, almidones, alginatos, alcoholes polivinílicos, gomas xantano, gomas guar, polisacáridos, pectinas, gelatinas y sus mezclas.
- 20.- La tableta masticable de conformidad con la reivindicación 15, caracterizada además porque el agente antigramuloso se selecciona del grupo que consiste en polioxietilenglicol, polietilenglicol y sus mezclas.
- 21.- La tableta masticable de conformidad con la reivindicación 15, caracterizada además porque la segunda capa de revestimiento consta de una mezcla de hidroxipropilmetilcelulosa y polietilenglicol.
- 22.- La tableta masticable de conformidad con la reivindicación 15, caracterizada además porque la relación en peso del polímero formador de película a agente antigramuloso en la segunda capa de revestimiento está en la escala de aproximadamente 10:90 a alrededor de 90:10.
- 23.- Una tableta de desintegración rápida que consta de las partículas que se reclaman en la reivindicación 1.
- 24.- La tableta de desintegración rápida de conformidad con la reivindicación 23, caracterizada además porque la primera capa de revestimiento o la segunda capa de revestimiento carece sustancialmente de plastificador.
- 25.- La tableta de desintegración rápida de conformidad con la reivindicación 23, caracterizada además porque el ingrediente activo es un fármaco antiinflamatorio no esteroideo, acetaminofen pseudoefedrina, fenilpropanolamina, clorfeniramina, dextrometorfan, difenhidramina, dimenhidrinato, meclizina, famotidina, loperamida, ranitidina, cimetidina, astemizol, loratadina, desloratadina, fexofenadina, cetirizina, antiácidos, sales farmacéuticamente aceptables de los mismos, sus metabolitos y sus mezclas.

- 26.- La tableta de desintegración rápida de conformidad con la reivindicación 23, caracterizada además porque cumple con la especificación de disolución de la USP para tabletas masticables de liberación inmediata que contienen el ingrediente activo particular.
- 27.- La tableta de desintegración rápida de conformidad con la reivindicación 23, caracterizada además porque el polímero formador de película se selecciona del grupo que consiste en hidroxipropilmetilcelulosa, hidroxipropilcelulosa y carboximetilcelulosa de sodio, almidones, alginatos, alcoholes polivinílicos, gomas xantano, gomas guar, polisacáridos, peptinas, gelatinas y sus mezclas.
- 28.- La tableta de desintegración rápida de conformidad con la reivindicación 23, caracterizada además porque el agente antigranuloso se selecciona del grupo que consiste en polioxietilenglicol, polietilenglicol y sus mezclas.
- 29.- La tableta de desintegración rápida de conformidad con la reivindicación 23, caracterizada además porque la capa segunda capa de revestimiento consta de una mezcla de hidroxipropilmetilcelulosa y polietilenglicol.
- 30.- La tableta de desintegración rápida de conformidad con la reivindicación 23, caracterizada además porque la relación en peso de polímero formador de película a agente antigranuloso en la segunda capa de revestimiento está en la escala de aproximadamente 10:90 a alrededor de 90:10.
- 31.- Un método de partículas de encubrimiento de textura que comprende un ingrediente activo, el cual comprende: a) aplicar una primera capa de revestimiento sustancialmente continua sobre las partículas, donde la primera capa de revestimiento comprende un agente de encubrimiento de sabor; b) aplicar una segunda capa de revestimiento en la superficie de la primera capa de revestimiento, la segunda capa de revestimiento comprende una mezcla de 1) un polímero formador de película y 2) un agente antigranuloso.
- 32.- El método de conformidad con la reivindicación 31, caracterizado además porque el ingrediente activo es un fármaco antiinflamatorio no esteroideo, acetaminofen pseudoefedrina, fenilpropanolamina, clorfeniramina, dextrometorfan, difenhidramina, dimenhidrinato, meclizina, famotidina, loperamida, ranitidina, cimetidina, astemizol, loratadina, desloratadina, fexofenadina, cetirizina, antiácidos, sales farmacéuticamente aceptables de los mismos, sus metabolitos y sus mezclas.

- 57
- 33.- El método de conformidad con la reivindicación 31, caracterizado además porque el polímero formador de película se selecciona del grupo que consiste en hidroxipropilmetilcelulosa, hidroxipropilcelulosa, hidroxietilcelulosa y carboximetilcelulosa de sodio, almidones, alginatos, alcoholes polivinílicos, gomas xantano, gomas guar, polisacáridos, pectinas, gelatinas y sus mezclas.
 - 34.- El método de conformidad con la reivindicación 31, caracterizado además porque el agente antigranuloso se selecciona del grupo que consiste en polioxietileno, polietilenglicol y sus mezclas.
 - 35.- El método de conformidad con la reivindicación 31, caracterizado además porque la segunda capa de revestimiento consta de una mezcla de hidroxipropilmetilcelulosa y polietilenglicol.
 - 36.- El método de conformidad con la reivindicación 31, caracterizado además porque la relación en peso de polímero formador de película a agente antigranuloso en la segunda capa de revestimiento está en la escala de aproximadamente 10:90 a alrededor de 90:10.
 - 37.- Una partícula de textura encubierta que comprende: a) un núcleo que contiene un ingrediente activo y b) una capa de revestimiento de encubrimiento de textura sobre la superficie del núcleo, la capa de revestimiento de encubrimiento de textura consta de i) un polímero formador de película; ii) un agente antigranuloso.
 - 38.- La partícula de conformidad con la reivindicación 37, caracterizada además porque el ingrediente activo es un fármaco antiinflamatorio no esteroideo, acetaminofen pseudoefedrina, fenilpropanolamina, clorfeniramina, dextrometorfan, difenhidramina, dimenhidrinato, meclizina, famotidina, loperamida, ranitidina, cimetidina, astemizol, loratadina, desloratadina, fexofenadina, cetirizina, antiácidos, sales farmacéuticamente aceptables de los mismos, sus metabolitos y sus mezclas.
 - 39.- La partícula de conformidad con la reivindicación 37, caracterizada además porque cumple con la especificación de disolución de la USP para formas de dosis de liberación inmediata que contienen el ingrediente activo particular.
 - 40.- La partícula de conformidad con la reivindicación 37, caracterizada además porque el polímero formador de película se selecciona del grupo que consiste en hidroxipropilmetilcelulosa, hidroxipropilcelulosa, hidroxietilcelulosa y carboximetilcelulosa de sodio, almidones, alginatos,

alcoholes polivinílicos, gomas xantano, gomas guar, polisacáridos, pectinas, gelatinas y sus mezclas.

- 41.- La partícula de conformidad con la reivindicación 37, caracterizada además porque el agente antigranuloso se selecciona del grupo que consiste en óxido de polietileno, polietilenglicol y sus mezclas.
- 42.- La partícula de conformidad con la reivindicación 37, caracterizada además porque la capa de revestimiento de encubrimiento de textura consta de una mezcla de hidroxipropilmetilcelulosa y polietilenglicol.
- 43.- La partícula de conformidad con la reivindicación 37, caracterizada además porque la relación en peso de polímero formador de película a agente antigranuloso en la capa de revestimiento de encubrimiento de textura está en la escala de aproximadamente 10:90 a alrededor de 90:10.
- 44.- La partícula de conformidad con la reivindicación 37, caracterizada además porque la relación en peso de polímero formador de película a agente antigranuloso en la capa de revestimiento de encubrimiento de textura está en la escala de aproximadamente 50:50.
- 45.- Una tableta que consta de las partículas que se reclaman en la reivindicación 37.
- 46.- Una tableta masticable que consta de las partículas que se reclaman en la reivindicación 37.
- 47.- La tableta masticable de conformidad con la reivindicación 46, caracterizada además porque el ingrediente activo es un fármaco antiinflamatorio no esteroideo acetaminofen pseudoefedrina, fenilpropanolamina, clorfeniramina, dextrometorfan, difenhidramina, dimenhidrinato, meclizina, famotidina, loperamida, ranitidina, cimetidina, astemizol, loratadina, desloratadina, fexofenadina, cetirizina, antiácidos, sales farmacéuticamente aceptables de los mismos, sus metabolitos y sus mezclas.
- 48.- La tableta masticable de conformidad con la reivindicación 46, caracterizada además porque el polímero formador de película se selecciona del grupo que consiste en hidroxipropilmetilcelulosa, hidroxipropilcelulosa, hidroxietilcelulosa y carboximetilcelulosa de sodio, almidones, alginatos, alcoholes polivinílicos, gomas xantano, gomas guar, polisacáridos, pectinas, gelatinas y sus mezclas.

- 49.- La tableta masticable de conformidad con la reivindicación 46, caracterizada además porque el agente antigranuloso se selecciona del grupo que consiste en polioxietilenglicol, polietilenglicol y sus mezclas.
- 50.- La tableta masticable de conformidad con la reivindicación 46, caracterizada además porque la capa de revestimiento de encubrimiento de textura consta de una mezcla de hidroxipropilmetilcelulosa y polietilenglicol.
- 51.- La tableta masticable de conformidad con la reivindicación 46, caracterizada además porque la relación en peso de polímero formador de película a agente antigranuloso en la capa de revestimiento de encubrimiento de textura está en la escala de aproximadamente 10:90 a alrededor de 90:10.
- 52.- Una tableta de desintegración rápida que consta de las partículas que se reclaman en la reivindicación 37.
- 53.- La tableta de desintegración rápida de conformidad con la reivindicación 52, caracterizada además porque el ingrediente activo es un fármaco antiinflamatorio no esteroideo, acetaminofen pseudoefedrina, fenilpropanolamina, clorfeniramina, dextrometorfan, difenhidramina, dimenhidrinato, meclizina, famotidina, loperamida, ranitidina, cimetidina, astemizol, loratadina, desloratadina, fexofenadina, cetirizina, antiácidos, sales farmacéuticamente aceptables de los mismos, sus metabolitos y sus mezclas.
- 54.- La tableta de desintegración rápida de conformidad con la reivindicación 52, caracterizada además porque el polímero formador de película se selecciona del grupo que consiste en hidroxipropilmetilcelulosa, hidroxipropilcelulosa, hidroxietilcelulosa y carboximetilcelulosa de sodio, almidones, alginatos, alcoholes polivinílicos, gomas xantano, gomas guar, polisacáridos, pectinas, gelatinas y sus mezclas.
- 55.- La tableta de desintegración rápida de conformidad con la reivindicación 52, caracterizada además porque el agente antigranuloso se selecciona del grupo que consiste en polioxietilenglicol, polietilenglicol y sus mezclas.
- 56.- La tableta de desintegración rápida de conformidad con la reivindicación 52, caracterizada además porque la capa de revestimiento de encubrimiento de textura consta de una mezcla de hidroxipropilmetilcelulosa y polietilenglicol.

- 60
- 57.- La tableta de desintegración rápida de conformidad con la reivindicación 52, caracterizada además porque la relación en peso de polímero formador de película a agente antigranuloso en la capa de revestimiento de encubrimiento de textura está en la escala de aproximadamente 10:90 a alrededor de 90:10.
- 58.- Un método para encubrir la textura de partículas que comprenden un ingrediente activo, dicho método comprende: a) aplicar una capa de revestimiento sobre el ingrediente activo, la capa de revestimiento que comprende una textura de 1) un polímero formador de película y 2) un agente antigranuloso.
- 59.- El método de conformidad con la reivindicación 58, caracterizado además porque el ingrediente activo es un fármaco antiinflamatorio no esteroideo, acetaminofen pseudoefedrina, fenilpropanolamina, clorfeniramina, dextrometorfan, difenhidramina, dimenhidrinato, meclizina, famotidina, loperamida, ranitidina, cimetidina, astemizol, loratadina, desloratadina, fexofenadina, cetirizina, antiácidos, sales farmacéuticamente aceptables de los mismos, sus metabolitos y sus mezclas.
- 60.- El método de conformidad con la reivindicación 58, caracterizado además porque el polímero formador de película se selecciona del grupo que consiste en hidroxipropilmetilcelulosa, hidroxipropilcelulosa, hidroxietilcelulosa y carboximetilcelulosa de sodio, almidones, alginatos, alcoholes polivinílicos, gomas xantano, gomas guar, polisacáridos, pectinas, gelatinas y sus mezclas.
- 61.- El método de conformidad con la reivindicación 58, caracterizado además porque el agente antigranuloso se selecciona del grupo que consiste en polioxietilenglicol, polietilenglicol y sus mezclas.
- 62.- El método de conformidad con la reivindicación 58, caracterizado además porque la capa de revestimiento consta de una mezcla de hidroxipropilmetilcelulosa y polietilenglicol.
- 63.- El método de conformidad con la reivindicación 58, caracterizado además porque la relación en peso de polímero formador de película a agente antigranuloso en la capa de revestimiento de encubrimiento de textura está en la escala de aproximadamente 10:90 a alrededor de 90:10.
- 64.- La partícula de conformidad con la reivindicación 37, caracterizada además porque la capa de revestimiento de encubrimiento de textura cubre sustancialmente el núcleo.

- 65.- Una tableta que comprende las partículas que se reclaman en la reivindicación 64.
- 66.- El método de conformidad con la reivindicación 58, caracterizado además porque la capa de revestimiento es sustancialmente continua.
- 67.- Una partícula de textura encubierta que comprende una matriz, dicha matriz consta de: a) un ingrediente activo; b) un polímero formador de película; y c) un agente antigranuloso, en donde el polímero formador de película y el agente antigranuloso están expuestos en la superficie de la partícula en una cantidad efectiva para encubrir la textura del ingrediente activo.
- 68.- La partícula de conformidad con la reivindicación 67, caracterizada además porque el diámetro promedio de dicha partícula es de aproximadamente 50 a 500 micras.
- 69.- La partícula de conformidad con la reivindicación 67, caracterizada además porque la relación en peso de polímero formador de película a agente antigranuloso es de aproximadamente 10:90 a alrededor de 90:10.
- 70.- La partícula de conformidad con la reivindicación 67, caracterizada además porque el polímero formador de película y el agente antigranuloso están presentes en una cantidad, con base en el peso de la partícula de textura encubierta, de aproximadamente 25 a alrededor de 90%.
- 71.- La partícula de conformidad con la reivindicación 67, caracterizada además porque está elaborada por secado por aspersión de una mezcla que comprende el ingrediente activo, un polímero formador de película y un agente antigranuloso.
- 72.- Un método para elaborar partículas de textura enmascarada que comprende un ingrediente activo, el método comprende secar por aspersión una mezcla que comprende a) un polímero formador de película y un agente antigranuloso que están presentes en una cantidad efectiva para encubrir la textura del ingrediente activo; b) el ingrediente activo.

62

PA 518204

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 01, 2002

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 09/745,243 ✓

FILING DATE: December 21, 2000



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

L. Edelen

L. EDELEN
Certifying Officer

63

12-22-00

A

12/21/00
3593 U.S. PTO
09/45243-1221 0

Please type a plus sign (+) inside this box ☐

UTILITY
PATENT APPLICATION
TRANSMITTAL

Attorney Docket No.	MCP-231
First Inventor	Parish et al
Title	Texture Masked Particles Containing an Active Ingredient
Express Mail Label No.	EL160825804US

(only for new nonprovisional applications under 37 CFR 1.53(a))

APPLICATION ELEMENTS

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

See MPEP Chapter 800 concerning utility patent application contents.

- ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(submit an original and a duplicate for fee processing)
- ☐ Applicant claims small entity status.
- ☒ Specification [Total Pages]
(Preferred arrangement set forth below)
 - Descriptive Title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
- ☐ Drawing(s) (35 USC 113) [Total Sheets]
- ☐ Oath or Declaration [Total Pages 3]
 - ☒ Newly unexecuted (original or copy)
 - ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
 - ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

- ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
- Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - ☐ Computer Readable Form (CRF)
 - ☐ Specification Sequence Listing on:
 - ☐ CD-ROM or CD-R (2 copies); or
 - ☐ paper
 - ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- ☐ Assignment Papers (cover sheet & document(s))
- ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
- ☐ English Translation Document (if applicable)
- ☐ Information Disclosure Statement
(IDS)/PTO-1449 ☐ Copies of IDS Citations
- ☐ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
- ☐ Request and Certifications under 35 U.S.C. 122
(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
- ☐ Other

6. ☐ Application Data Sheet. See 37 CFR 1.76

18. ☐ If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-Part (CIP) of prior application No.: , filed .
Prior application Information: Examiner Group Art Unit:
For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label or ☒ Correspondence Address below

Name: Phillip S. Johnson, Esq.
Address: Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003

The PTO did not receive the following listed item(s): Fee Transmittal Form

19. TELEPHONE CONTACT

Please direct all telephone calls or telefaxes to Michele G. Mangini at:
Telephone: (732) 524-2810 Fax: (732) 524-2808

19. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	Michele G. Mangini	Reg. No. 36,806
SIGNATURE		
DATE	December 21, 2000	

6A

DOCKET NO. MCP-231

IN THE UNITED STATES
PATENT AND TRADEMARK OFFICE

Applicant: Parikh et al

For : Texture Masked Particles Containing An Active
Ingredient

Express Mail Certificate

"Express Mail" mailing number: EL190925804US


Date of Deposit: December 21, 2000

I hereby certify that this complete application, including specification pages (21)with 72 claims, and unexecuted declaration, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

An Executed Combined Declaration and Power of Attorney will be submitted to the United States Patent and Trademark Office upon receipt of the U.S. Serial Number for this patent application.

Alwin Haywood

(Typed or printed name of person mailing paper or fee)



(Signature of person mailing paper or fee)

001221.24243.122100

65

FEE TRANSMITTAL	<i>Complete if Known</i>	
	Application Number	
	Filing Date	December 21, 2000
	First Named Inventor	Parish et al
	Group Art Unit	
	Examiner Name	
	Attorney Docket Number	MCP-231

FEE CALCULATION

CLAIMS AS FILED

(1)	(2)	(3)	(4)	(5)
FOR:	NUMBER FILED	NUMBER EXTRA	RATE	BASIC FEE \$710.00
TOTAL CLAIMS	72 - 20 =	52	x 18.00	\$936.00
INDEPENDENT CLAIMS	5-3	2	x 80.00	\$160.00
MULTIPLE DEPENDENT CLAIMS	☐	N/A	\$270.00	
			TOTAL FEES	\$1806.00

METHOD OF PAYMENT

- ☒ Please charge Deposit Account No. 10-0750/MCP-231/MGM in the amount of \$1,806.00. Three copies of this sheet are enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this communication, or credit any overpayment, to Account No. 10-0750/MCP-231/MGM. Three copies of this sheet are enclosed.

SUBMITTED BY:		<i>Complete (if applicable)</i>
Typed or Printed Name	Michele G. Mangini	Reg. No. 36,806
Signature		Date: December 21, 2000 Deposit Account No. 10-0750/MCP-231/MGM

09745243.122100

TEXTURE MASKED
PARTICLES CONTAINING AN ACTIVE INGREDIENT

5 This invention relates to texture masked particles containing an active ingredient and a polymeric overcoating mixture of a water soluble or water swellable film forming polymer and an anti-grit agent. The coated particles may be used to make chewable tablets or rapidly disintegrating tablets that conveniently may be administered without water.

Background of the Invention

10 Pharmaceuticals intended for oral administration are typically provided in solid form as tablets, capsules, pills, lozenges, or granules. Tablets are swallowed whole, chewed in the mouth, or dissolved in the oral cavity. Chewable tablets are typically made from a mixture including active drug particles, and other inactive ingredients (excipients), and are often employed for the administration of pharmaceuticals where it is impractical to provide a tablet for swallowing whole.
15 With chewable tablets, the act of chewing helps to break up the tablet particles as the tablet disintegrates and may increase the rate of absorption by the digestive tract. Chewable tablets are often utilized to improve drug administration in pediatric and geriatric patients.

Certain drug particles have a bitter or otherwise unpleasant taste. In order to make palatable chewable tablets from these, their taste must be masked for example by dispersing or
20 coating the particles with a coating composition as disclosed in, for example, United States Patent Numbers 4,851,226; 5,489,436; 5,529,783; 5,215,755; 5,260,072; 5,460,825; 4,800,087; 5,814,332; and 5,076,114, which are incorporated by reference herein. In general, such efforts have focused on masking the unpleasant taste of the drug by coating the drug particles with polymers designed to delay dissolution until the drug has cleared the oral cavity. However, after
25 the other ingredients in the tablet matrix dissolve away, the coated drug particles are often left in the mouth with their gritty, sandy texture. This is particularly of concern with rapidly disintegrating dosage forms that are becoming more popular.

Various attempts have been made to enhance the texture of drug particles in order to prevent their adhesion to the oral mucosa upon ingestion. For example, WO88/06893 discloses
30 an oral composition comprised of an active substance and a gelling or swelling agent capable of forming a viscous medium around the particles in an aqueous carrier. Disadvantageously, such compositions must be disintegrated in water to form a liquid suspension before ingestion for purposes of facilitating the ease of quickly swallowing the composition without chewing.

It would be desirable to have an oral dosage form that effectively masks the texture or
35 both the taste and the texture of active materials, such as drug particles, during ingestion, which thereby obviates the need for consumption with water; and that also may be chewed.

Summary of the Invention

40 The present invention provides a texture masked particle comprising, consisting of, or consisting essentially of:

- a) a core containing an active ingredient;
- b) a first coating layer comprised of a taste masking agent that substantially covers the core; and
- c) a second coating layer on the surface of the first coating layer, the second coating layer comprised of, consisting of, or consisting essentially of:
 - i) a film forming polymer; and
 - ii) an anti-grit agent.

The invention also provides a texture masked particle comprising, consisting of, or consisting essentially of:

- a) a core containing an active ingredient; and
- b) a texture masking coating layer on the surface of the core, the texture masking coating layer comprised of, consisting of, or consisting essentially of
 - i) a film forming polymer; and
 - ii) an anti-grit agent.

The invention further provides a method of texture masking particles comprising an active ingredient, which comprises, consists of, or consists essentially of:

- a) applying a substantially continuous first coating layer over the particles, the first coating layer comprising a taste masking agent; and
- b) applying a second coating layer over the first coating layer, the second coating layer comprising, consisting of, or consisting essentially of a mixture of a) a film forming polymer; and b) an anti-grit agent.

The invention further provides a method of texture masking particles comprising an active ingredient, which comprises, consists of or consists essentially of:

- applying a coating layer on the surface of a core comprising the active ingredient, the coating layer comprising, consisting of, or consisting essentially of a mixture of a) a film forming polymer; and b) an anti-grit agent.

The invention further provides a method of making texture masked particles comprising an active ingredient, which comprises, consists of or consists essentially of:

spray-drying a mixture comprising

- a) a film forming polymer and an anti-grit agent which are both present in an amount effective for texture masking the active ingredient; and
- b) the active ingredient.

The invention further provides a texture masked particle comprised of a matrix, the matrix comprising, consisting of, or consisting essentially of:

- a) an active ingredient,
- b) a film forming polymer, and
- c) an anti-grit agent,

wherein the film forming polymer and anti-grit agent are exposed at the surface of the particle in an amount effective for texture masking the active ingredient.

In accordance with this invention, texture masked pharmaceutical formulations having an immediate release profile may be made using an overcoating comprising a mixture of a film forming polymer and an anti-grit agent. This texture masking overcoating not only overcomes the gritty texture of the drug particles, but also facilitates ease of swallowing. Moreover, the formulations may conveniently be ingested without the need for water. The overcoated particles of the invention advantageously exhibit sufficient elasticity without the need for added plasticizers to maintain integrity during tableting and prevent release of the drug into the mouth during chewing. Chewable tablets made from these coated particles have excellent taste and yet surprisingly exhibit an immediate release profile.

Detailed Description of the Invention

As used herein, the term "substantially covers" or "substantially continuous" means that the coating is generally continuous and generally covers the entire surface of the core or underlying layer, so that little to none of the active ingredient or underlying layer is exposed.

The core of the texture masked particle may comprise any one of a number of active ingredients. Suitable active ingredients broadly include pharmaceutically active ingredients, dietary supplements, nutritionals, nutraceuticals, and the like. More specifically these include analgesics, decongestants, expectorants, antitussives, antihistamines, gastrointestinal agents, diuretics, bronchodilators, sleep-inducing agents, vitamins, minerals, anti-infectives, nutrients, and mixtures thereof. One class of preferred active ingredients include nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, rofecoxib, celecoxib, and aspirin. The active ingredient may alternatively be selected from acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, loperamide, ranitidine, cimetidine, bisacodyl, psyllium, astemizole, loratadine, desloratadine, fexofenadine, cetirizine, antacids, mixtures thereof and pharmaceutically acceptable salts or metabolites thereof. Most preferably, the active ingredient is selected from the group consisting of acetaminophen, ibuprofen, pseudoephedrine, dextromethorphan, diphenhydramine, chlorpheniramine, loratadine, calcium carbonate, magnesium hydroxide, magnesium carbonate, magnesium oxide, aluminum hydroxide, mixtures thereof, and pharmaceutically acceptable salts thereof.

The core of the particle may comprise pure, crystalline active ingredient, or a mixture of active ingredient with optional ingredients, such as binders, excipients and the like known in the art. The core may be formed using a variety of well known granulation methods, including high shear wet granulation, spray drying, and fluid bed granulation (including rotary fluid bed granulation). Preferably, the particle core is made by fluid bed granulation. Preferably the average diameter of the core of the particle is from about 80 to about 300 microns.

In one embodiment, the first coating layer, which is comprised of a taste masking agent, substantially covers the core. Examples of suitable taste masking agents include, but are not limited to cellulose acetate, ethylcellulose, poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride), which is commercially available from Rohm Pharma

under the tradename, "EUDRAGIT", hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and mixtures thereof.

In another embodiment, the taste masking agent is comprised of a mixture of a) an enteric polymer and b) an insoluble film forming polymer. The enteric polymer may be selected from any one of a variety of known enteric polymers, such as hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, polyvinylacetate phthalate, and polymethacrylate-based polymers such as poly(methacrylic acid, methyl methacrylate) 1:2, which is commercially available from Rohm Pharma GmbH under the tradename, "EUDRAGIT S" polymers, and poly(methacrylic acid, methyl methacrylate) 1:1, which is commercially available from Rohm Pharma GmbH under the tradename, "EUDRAGIT L" polymers. Combinations of enteric polymers may also be used.

Preferably, the enteric polymer is selected from non-acrylate compounds, specifically hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, and polyvinylacetate phthalate. Non-acrylates are preferred because acrylate polymers tend to become tacky and agglomerate at high temperature. Cellulose polymers are more heat stable than acrylate polymers. In addition, acrylate polymers are known to have a characteristic, slightly unpleasant taste, whereas cellulose polymers have a more neutral taste profile.

The insoluble film forming polymer may also be selected from a number of known compounds, including cellulose acetate, ethylcellulose, and poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:0.1, which is commercially available from Rohm Pharma under the tradename, "EUDRAGIT RS". One or more than one insoluble film forming polymer may be used. Preferably, the insoluble film forming polymer is impermeable and does not swell in an aqueous environment. More preferably, the insoluble film forming polymer is selected from cellulose acetate and ethylcellulose.

The weight ratio of enteric polymer to insoluble film forming polymer in the polymeric coating is preferably in the range of about 20:80 to about 80:20, more preferably about 40:60 to about 70:30.

The taste masking agent may be combined with other optional ingredients. In one embodiment, the taste masking agent is combined with one or more non-enteric, water soluble polymers, such as hydroxypropyl cellulose and poly(ethyl acrylate, methyl methacrylate, which is commercially available from Rohm Pharma GmbH under the tradename, "EUDRAGIT NE 30D." When a non-enteric, water soluble polymer is present in the polymeric coating, the level of non-enteric, water soluble polymer is preferably about 10 to about 30% of the polymeric coating.

The taste masking agent may also optionally be combined with a surfactant. Suitable surfactants include both ionic and non-ionic materials from both synthetic and natural origins, including but not limited to lecithin, glyceryl esters, sugar esters, polysorbates, mono and diglycerides of fatty acids, propylene glycol esters, sucrose fatty acid esters, polyoxyethylene derivatives of sorbitan fatty acid esters, and mixtures thereof. Examples of useful polysorbates include sorbitan trioleate, sorbitan monopalmitate, sorbitan monooleate, propylene glycol

monoaurate, glycerol monostearate, diglycerol monostearate, glycerol lactyl-palmitate. Lactic acid derivatives include sodium stearyl lactylate and calcium stearyl lactylate. When a surfactant is present in the first coating layer, the level of surfactant is present in an amount, based upon the total weight of the first coating layer, from about 2% to about 10%.

5 A particularly preferred first layer coating comprises about 53 wt % hydroxypropyl methylcellulose phthalate, about 43 wt % cellulose acetate, and about 4 wt % polysorbate.

The first layer coating is preferably applied to the particle core in the form of a solution using fluidized bed technology, such as Wurster coating or rotor coating. Useful solvents include any of the pharmaceutically suitable organic solvents such as acetone, methanol, ethanol, 10 isopropanol; aqueous solvents such as water, and mixtures thereof. One suitable solvent mixture includes acetone and water at a ratio from about 85:15 to about 95:5.

The thickness of the first layer coating on the core is typically from about 1 micron to about 20 microns, e.g. from about 2 microns to about 15 microns or from about 4 to about 9 microns. The first layer coating may be present in an amount, based upon the total weight of the taste 15 masked particle before the addition of the texture masking overcoating thereto, from about 5 percent to about 50 percent, e.g. from about 15 percent to about 25 percent.

The first layer coating is then overcoated with a texture masking coating layer comprised of a water soluble and/or water swellable film forming polymer and an anti-grit agent. Examples of suitable film forming polymers include, but are not limited to, all pharmaceutically suitable water 20 soluble cellulosic polymers that nonexclusively include hydroxypropyl methylcellulose ("HPMC"), hydroxypropyl cellulose ("HPC"), hydroxyethyl cellulose ("HEC"), and sodium carboxy methyl cellulose ("sodium CMC"); starches; alginates; polyvinyl alcohols; xanthan gums; guar gums; polysaccharides; pectins; gelatins; and mixtures thereof with HPMC being preferred. Examples of suitable anti-grit agents include, but are not limited to polyethylene glycol ("PEG"), polyethylene 25 oxide ("PEO"), mineral oils, waxes, silicone derivatives, and mixtures thereof, with PEG and PEO being preferred, and PEG being particularly preferred.

The weight ratio of film-forming polymer to anti-grit agent in the texture masking layer overcoating may be in the range of about 10:90 to about 90:10, e.g. about 20:80 to about 80:20, about 80:40 to about 40:60, or about 50:50 to about 50:50.

30 In one embodiment, the texture masking overcoating layer is comprised of about 50 wt % HPMC and about 50 wt % PEG. A particularly preferred HPMC is substitution type 2910 (USP) or 2208 (USP), and has a viscosity of about 8 centipoise in a 2% aqueous solution. A particularly preferred PEG has a molecular weight of about 8000 daltons.

Any of the optional ingredients set forth above for use in the first layer may be used in the 35 same amounts in the texture masking overcoating layer.

The thickness of the texture masking overcoating on the coated core is typically from about 1 to about 20 microns, e.g., from about 2 to about 15 microns or from about 4 microns to about 9 microns. The texture masking overcoating is present in an amount, based upon the weight of the taste masked particle, from about 2 percent to about 40 percent, e.g. from about 3 40 percent to about 20 percent or about 5 percent to about 10 percent.

00745243.122100

00745243-122100

The texture masking overcoating may be applied to the coated core via any of the methods set forth above for coating the core with the first taste masking layer. A preferred method for applying the texture masking overcoating is to dissolve the film forming polymer and anti-grit agent in a suitable solvent, then apply the coating solution to the particle core, which is either coated with a taste masking layer or is uncoated, using fluidized bed technology such as Wurster coating or rotor coating. Useful solvents include any of the pharmaceutically suitable organic solvents such as acetone, methanol, ethanol, isopropanol; aqueous solvents such as water, and mixtures thereof. A preferred solvent mixture is ethanol and water. In this embodiment the ratio of ethanol to water in the coating solution is typically from about 10:90 to about 90:10, e.g. from about 50:50 to about 80:20. One skilled in the art may readily appreciate that the coating conditions, such as solution spray rate, drying air temperature and flow rate must be adjusted in order to achieve an equilibrium between the rate of application of the liquid coating solution, and the rate of evaporation of the solvents such that the texture masking coating can be deposited uniformly on the particle to form a complete film without overwetting the particle surface. Details of these methods are well known in the art and set forth in, for example, Lieberman et al., "Pharmaceutical Dosage Forms - Tablets: Volume 3", Chapter 3: Particle Coating Methods (1990), which is incorporated by reference herein.

In another embodiment, the uncoated core layer, i.e. the core layer without a tastemasking coating layer, may be substantially covered with the texture masking overcoating. Any of the optional ingredients set forth above for use in the first layer may be added in the same amounts to the texture masking overcoating. In this embodiment, the texture masking overcoating may be present in an amount, based upon the total weight of core and texture masking overcoating, from about 2 percent to about 40 percent, e.g. from about 3 percent to about 20 weight percent. The texture masking overcoating may be applied to the uncoated core via any of the methods set forth above for applying the tastemasking coating to the core.

In yet another embodiment, the texture masked particle may be manufactured by spray-drying whereby in general the active ingredient is suspended or dissolved, along with the film forming polymer and anti-grit agent and optional other ingredients, in a suitable solvent. Suitable solvents include any of the pharmaceutically suitable organic solvents such as acetone, methanol, ethanol, isopropanol; aqueous solvents such as water, and mixtures thereof. The solution or suspension is then sprayed into a hot drying air stream, resulting in evaporation of the solvent. One skilled in the art may readily appreciate that the spray-drying conditions, such as dryer configuration, spray rate, atomization conditions, drying air temperature and flow rate must be adjusted in order to achieve optimum particle size and morphology. Details of these methods are well known in the art and set forth in, for example, Masters, "Spray Drying Handbook, (1979), which is incorporated by reference herein.

In the embodiment wherein the texture masked particle is produced via spray-drying, the texture masked particle comprises a matrix of active ingredient, film forming polymer, and anti-grit agent such that all of these components may be present at the surface of the particle. The particle will be texture-masked by the presence of the film forming polymer and anti-grit agent at the

particle surface in an amount effective for texture masking the active ingredient. The texture masked particles of this embodiment will range in average diameter from about 50 to about 500 microns; e.g. from about 80 to about 400 microns. The weight ratio of film-forming polymer to anti-grit agent in the spray-dried texture masked particle may be in the range of about 10:90 to about 90:10, e.g. about 20:80 to about 80:20, about 60:40 to about 40:60, or about 50:50 to about 50:50. The film forming polymer and the anti-grit agent together are present in an amount, based on the weight of the texture masked spray-dried particle, from about 25 to about 90%, e.g. about 40 to about 80%, or about 50 to about 75%.

Optional ingredients suitable for use in the spray-dried, texture-masked particles include but are not limited to fillers, including water soluble compressible carbohydrates such as sucrose, mannitol, sorbitol, maltitol, xylitol, erythritol, lactose, and mixtures thereof; conventional dry binders including cellulose, cellulosic derivatives, polyvinyl pyrrolidone, starch, modified starch, maltodextrin, and mixtures thereof, and in particular microcrystalline cellulose, maltodextrin, and starch; sweeteners including aspartame, acesulfame potassium, sucralose and saccharin; disintegrants such as microcrystalline cellulose, starch, sodium starch glycolate, crosslinked polyvinylpyrrolidone, crosslinked carboxymethylcellulose; preservatives, flavors, acidulants, antioxidants, glidants, surfactants, and coloring agents.

Tablets comprised of the particles of the present invention may be made by any means known in the art. More specifically, these tablets may be comprised of a mixture of the taste masked and texture masked particles, the texture masked particles, or combinations of the same, along with common tablet excipients known in the art.

Conventional methods for tablet production include direct compression ("dry blending"), dry granulation followed by compression, and wet granulation followed by drying and compression. Other methods include the use of compacting roller technology such as a chilsonator or drop roller, or molding, casting, or extrusion technologies. All of these methods are well known in the art, and are described in detail in, for example, Lachman, et al., "The Theory and Practice of Industrial Pharmacy," Chapter 11, (3rd Ed. 1986), which is incorporated by reference herein. Preferably the tablets may be formed by the direct compression method, which involves directly compacting a blend of the taste masked and texture masked particles, the texture masked particles, or combinations of the same, and any other appropriate optional ingredients. After blending, a pre-determined volume of particles is filled into a die cavity of a rotary tablet press, which continuously rotates as part of a "die table" from the filling position to a compaction position. The particles are compacted between an upper punch and a lower punch to an ejection position, at which the resulting tablet is pushed from the die cavity by the lower punch and guided to an ejection chute by a stationary "take-off" bar.

In embodiments wherein a chewable tablet is desired, the degree of particle compaction is controlled so that the resulting tablets are relatively soft, i.e. they have a hardness of up to about 15 kiloponds per square centimeter (kp/cm²), e.g. from about 1 kp/cm² to about 10 kp/cm² or from about 2 kp/cm² to about 6 kp/cm². "Hardness" is a term used in the art to describe the diametrical breaking strength as measured by conventional pharmaceutical hardness testing

09745243-122100

equipment, such as a Schleuniger Hardness Tester. In order to compare values across different size tablets, the breaking strength is normalized for the area of the break (which may be approximated as the tablet diameter times the thickness). This normalized value, expressed in kp/cm^2 , is sometimes referred in the art as tablet tensile strength. A general discussion of tablet hardness testing is found in Lieberman et al., *Pharmaceutical Dosage Forms – Tablets*, Volume 2, 2nd ed., Marcel Dekker Inc., 1990, pp. 213 – 217, 327 – 329 (hereinafter “Lieberman”).

The active ingredient is present in the chewable tablet in a therapeutically effective amount, which is an amount that produces the desired therapeutic response upon oral administration and can be readily determined by one skilled in the art. In determining such amounts, the particular active ingredient being administered, the bioavailability characteristics of the active ingredient, the dose regime, the age and weight of the patient, and other factors must be considered.

The chewable tablet may contain other conventional ingredients such as fillers, including water soluble compressible carbohydrates such as sucrose, mannitol, sorbitol, maltitol, xylitol, erythritol, lactose, and mixtures thereof; conventional dry binders including cellulose, cellulosic derivatives, polyvinyl pyrrolidone, starch, modified starch, and mixtures thereof, and in particular microcrystalline cellulose; sweeteners including aspartame, acesulfame potassium, sucralose and saccharin; disintegrants such as microcrystalline cellulose, starch, sodium starch glycolate, crosslinked polyvinylpyrrolidone, crosslinked carboxymethylcellulose; and lubricants, such as magnesium stearate, stearic acid, talc, and waxes. The chewable tablet may also incorporate pharmaceutically acceptable adjuvants, including for example preservatives, flavors, acidulants, antioxidants, glidants, surfactants, and coloring agents.

Texture masked particles produced in accordance with the present invention advantageously may be used for immediate release applications because the texture masking coating does not retard the dissolution of the active ingredient. Preferably the texture masked particles meet the USP dissolution specifications for the specific active ingredient they contain. In a preferred embodiment for the active ingredient acetaminophen, at least about 70% of the active ingredient is released in 45 minutes from particles tested using USP Dissolution Apparatus II (paddle method) in pH 5.8 phosphate buffer at 75 rpm. In a preferred embodiment for the active ingredient ibuprofen, at least about 70% of the active ingredient is released in 30 minutes from particles tested using USP dissolution apparatus II (paddle method) in pH 7.2 phosphate buffer at 150 rpm.

Specific embodiments of the present invention are illustrated by way of the following examples. This invention is not confined to the specific limitations set forth in these examples, but rather to the scope of the appended claims. Unless otherwise stated, the percentages and ratios given below are by weight.

09745243-122100

Examples

Example 1. Preparation of comparative chewable tablets

The following ingredients set forth below in Table A were placed in a plastic bag and blended via inverting the bag 100 times:

Table A: Components of Chewable Particles

Component Name	Amount Used (mg/tablet)
Ethylcellulose encapsulated acetaminophen*	274.7
Aspartame****	11.55
Acesulfame Potassium**	5.78
Citric acid***	2.00
Granular mannitol****	500
Fumaric acid****	20
Microcrystalline cellulose***	77
Orange flavor****	2

* comprising, based upon total component weight, a 94.5% acetaminophen core surrounded by a 5.5% ethylcellulose coating layer and available from Eurand America;

** available from Hoechst, GmbH under the tradename, "SUNETT;"

*** available from FMC Corporation under the tradename, "AVICEL PH101;"

**** These components are readily available and may be commercially purchased from any of the suppliers set forth in the "Handbook of Pharmaceutical Excipients (2nd Ed. 1994).

After adding 5.78 mg of magnesium stearate thereto, the resulting mixture was further blended by inverting the bag for an additional 20 times.

The resulting blend was then removed from the bag and compressed on a rotary tablet press at 40 rpm using 19/32" diameter flat faced beveled edge tablet tooling in order to yield tablets having a weight of 898.8 mg, a hardness of 3.1 kp as determined by the Hardness test set forth in Lieberman, and a thickness of 0.19 inches.

Example 2: Preparation of Texture-Masked Particles

A. Preparation of Texture-Masking Coating Solution:

A texture masking coating solution was prepared by dispersing equal amount of hydroxypropylmethyl cellulose and polyethylene glycol 800 together with acesulfame potassium (1% of solids) in a solvent comprising 77% ethanol and 23% water so that the solid materials represented 10% of the finished solution. The components of the finished solution are set forth in Table B below:

09745243-122100

Table B: Texture Masking coating Solution Composition

Component Name	Amount Used (g)
Ethanol***	604.72
Purified water	177.89
Hydroxypropylmethyl cellulose*	43.05
Polyethylene glycol 8000***	43.05
Acesulfame potassium**	0.87
Total	869.58

* available from Shin Etsu under the tradename, "PHARMACOAT 805;"

** available from Hoechst, GmbH under the tradename, "SUNETT;"

5 *** These components are readily available and may be commercially purchased from any of the suppliers set forth in the "Handbook of Pharmaceutical Excipients (2nd Ed. 1994).

B. Coating the Active Ingredient with Texture Masking Solution

10 1000 g of the encapsulated acetaminophen starting material from Example 1 were charged into a rotary fluid bed coater (Glett GPCG-5). The powder bed was mobilized using a rotor speed of 300 rpm and air volume of 0.65 inches of water. The texture masking coating solution was sprayed onto the particles through tangentially oriented nozzles at a rate of 30 g per minute. Inlet air temperature was 50°C. After all of the solution was sprayed, the resulting texture masked coated particles were dried at a decreased rotor speed of 100 rpm for 5 minutes. The final dried batch weighed 1061 g (97% yield). The level of the texture masking coating materials was 7% by weight of the total finished texture masked and taste masked coated particles. The resulting coated particles had an average diameter of 380 microns with a standard deviation of 70 microns according to a normal distribution model ($r^2=0.964$). 73.8% of the particles had an average diameter between 300 and 425 microns.

20 **Example 3. Preparation of chewable tablets**

25 Coated particles from Example 2 (7% texture masking overcoating level of HPMC/PEG 8000 on ethylcellulose-coated acetaminophen) were blended with aspartame, acesulfame potassium, citric acid, granular mannitol, fumaric acid, microcrystalline cellulose, and flavor in a plastic bag by inverting 100 times. Magnesium stearate was added, and the mixture was further blended by inverting 20 times. The components of the resulting blend are set forth in Table C below:

745243-122100

75

Table C: Components of Chewable Blend

Component Name	Amount Used (mg / tablet)
Encapsulated and overcoated acetaminophen (87.9% active)*	290.7
Aspartame***	11.55
Acesulfame Potassium**	5.78
Citric Acid ***	2.00
Mannitol ***	500
Microcrystalline cellulose ****	77
Fumaric Acid NF ***	20
Orange flavor***	2
Magnesium stearate***	5.78
TOTAL	914.81

* Prepared in Example 2;

** available from Hoechst, GmbH under the tradename, "SUNETT"

*** These components are readily available and may be commercially purchased from any of the suppliers set forth in the "Handbook of Pharmaceutical Excipients (2nd Ed. 1994).

**** available from FMC Corporation under the tradename, "AVICEL PH101;"

The resulting blend was compressed on a rotary tablet press at 40 rpm using 19/32" diameter flat faced beveled edge tablet tooling to yield tablets having an average tablet weight of 914.8 mg, a tablet hardness of 3.1 kp as determined by the Hardness test in Lieberman, and a tablet thickness of 0.2 inches. Friability by USP method was 3.3%.

Example 4: Evaluation of chewable tablets from Examples 1 and 3

The tablets prepared in Examples 1 and 3, respectively, were independently sampled by panelists, who evaluated each respective tablet on the basis of taste, texture, and dissolution.

Both tablets were found to have had a similar taste, with a very slight bitterness detected by most panelists. The tablets from Example 1 were found to have had a perceptible grittiness, which ranged from "slight" to "obvious," and a rough surface. By contrast, the "texture-masked" particles of the present invention produced in accordance with Example 3 were found to have had no grittiness, a smooth texture and a "good melt-away," i.e. the tablet was rapidly cleared from the oral cavity with minimal chewing required.

The tablets from Example 1 and Example 3 were also evaluated for dissolution by USP paddle method (Apparatus II) in a pH 5.8 phosphate buffer at 75 rpm. 100% of the acetaminophen active ingredient was released from the tablets of Example 1 and Example 3 in 45 minutes.

001221-60

This Example showed that although the texture masked overcoated tablets of the present invention had a flavor similar to that of the prior art tablets, the former were smoother and less gritty. As a result, the texture masked overcoated tablets are more suited for chewable tablet form.

09745243-122100

We claim:

- 09745243-122100
- 5
- 10
- 15
- 20
- 25
- 30
- 35
- 40
1. A texture masked particle comprising
 - a) a core containing an active ingredient;
 - b) a first coating layer comprised of a taste masking agent that substantially covers the core; and
 - c) a second coating layer on the surface of the first coating layer, the second coating layer comprised of
 - i) a film forming polymer; and
 - ii) an anti-grit agent.
 2. The particle of claim 1, wherein the second coating layer substantially covers the first coating layer.
 3. The particle of claim 1, wherein the active ingredient is selected from the group consisting of a nonsteroidal anti-inflammatory drug, acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, loperamide, ranitidine, cimetidine, astemizole, loratadine, desloratadine, fexofenadine, cetirizine, entecavir, pharmaceutically acceptable salts thereof, metabolites thereof, and mixtures thereof.
 4. The particle of claim 1, wherein the taste masking agent is comprised of a mixture of a) an enteric polymer; and b) an insoluble film forming polymer.
 5. The particle of claim 4, wherein the enteric polymer is selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, and mixtures thereof.
 6. The particle of claim 4, wherein the insoluble film forming polymer is selected from the group consisting of cellulose acetate, ethylcellulose, and mixtures thereof.
 7. The particle of claim 4, wherein the weight ratio of enteric polymer to insoluble film forming polymer in the first coating layer is in the range of about 20:80 to about 80:20.
 8. The particle of claim 1 which meets the USP dissolution specification for immediate release dosage forms containing the particular active ingredient.
 9. The particle of claim 1 wherein the film forming polymer is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and

sodium carboxy methyl cellulose, starches, alginates, polyvinyl alcohols, xanthan gums, guar gums, polysaccharides, pectins, gelatins, and mixtures thereof.

5 10. The particle of claim 1 wherein the anti-grit agent is selected from the group consisting of polyethylene oxide, polyethylene glycol, and mixtures thereof.

 11. The particle of claim 1 wherein the second coating layer is comprised of a mixture of hydroxypropyl methylcellulose and polyethylene glycol.

10 12. The particle of claim 1 wherein the weight ratio of film forming polymer to anti-grit agent in the second coating layer is in the range of about 10:90 to about 90:10.

 13. The particle of claim 1 wherein the weight ratio of film forming polymer to anti-grit agent in the second coating layer is in the range of about 50:50.

15 14. A tablet comprised of the particles of claim 1.

 15. A chewable tablet comprised of the particles of claim 1.

20 16. The chewable tablet of claim 15, wherein the first coating layer is substantially free of plasticizer.

25 17. The chewable tablet of claim 15, wherein the active ingredient is a nonsteroidal anti-inflammatory drug, acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, loperamide, ranitidine, cimetidine, astemizole, loratadine, desloratadine, fexofenadine, cetirizine, antacids, pharmaceutically acceptable salts thereof, metabolites thereof, and mixtures thereof.

30 18. The chewable tablet of claim 15 which meets the USP dissolution specification for immediate release chewable tablets containing the particular active ingredient.

35 19. The chewable tablet of claim 15 wherein the film forming polymer is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and sodium carboxy methyl cellulose, starches, alginates, polyvinyl alcohols, xanthan gums, guar gums, polysaccharides, pectins, gelatins, and mixtures thereof.

 20. The chewable tablet of claim 15 wherein the anti-grit agent is selected from the group consisting of polyoxyethylene glycol, polyethylene glycol, and mixtures thereof.

001227-84254760

21. The chewable tablet of claim 15 wherein the second coating layer is comprised of a mixture of hydroxypropyl methylcellulose and polyethylene glycol.

22. The chewable tablet of claim 15 wherein the weight ratio of film forming polymer to anti-grit agent in the second coating layer is in the range of about 10:90 to about 90:10.

23. A rapidly disintegrating tablet comprised of the particles of claim 1.

24. The rapidly disintegrating tablet of claim 23, wherein the first coating layer or the second coating layer is substantially free of plasticizer.

25. The rapidly disintegrating tablet of claim 23, wherein the active ingredient is a nonsteroidal anti-inflammatory drug, acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, loperamide, ranitidine, cimetidine, esomeprazole, loratadine, desloratadine, fexofenadine, cetirizine, antacids, pharmaceutically acceptable salts thereof, metabolites thereof, and mixtures thereof.

26. The rapidly disintegrating tablet of claim 23 which meets the USP dissolution specification for immediate release chewable tablets containing the particular active ingredient.

27. The rapidly disintegrating tablet of claim 23 wherein the film forming polymer is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and sodium carboxy methyl cellulose, starches, alginates, polyvinyl alcohols, xanthan gums, guar gums, polysaccharides, pectins, gelatins, and mixtures thereof.

28. The rapidly disintegrating tablet of claim 23 wherein the anti-grit agent is selected from the group consisting of polyoxyethylene glycol, polyethylene glycol, and mixtures thereof.

29. The rapidly disintegrating tablet of claim 23 wherein the second coating layer is comprised of a mixture of hydroxypropyl methylcellulose and polyethylene glycol.

30. The rapidly disintegrating tablet of claim 23 wherein the weight ratio of film forming polymer to anti-grit agent in the second coating layer is in the range of about 10:90 to about 90:10.

31. A method of texture masking particles comprising an active ingredient, which comprises:

a) applying a substantially continuous first coating layer over the particles, the first coating layer comprising a taste masking agent; and

b) applying a second coating layer on the surface of the first coating layer, the second coating layer comprising a mixture of 1) a film forming polymer; and 2) an anti-grit agent.

32. The method of claim 31, wherein the active ingredient is a nonsteroidal anti-inflammatory drug, acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, loperamide, ranitidine, cimetidine, astemizole, loratadine, desloratadine, fexofenadine, cetirizine, antacids, pharmaceutically acceptable salts thereof, metabolites thereof, and mixtures thereof.

33. The method of claim 31 wherein the film forming polymer is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and sodium carboxy methyl cellulose, starches, alginates, polyvinyl alcohols, xanthan gums, guar gums, polysaccharides, pectins, gelatins, and mixtures thereof.

34. The method of claim 31 wherein the anti-grit agent is selected from the group consisting of polyoxyethylene, polyethylene glycol, and mixtures thereof.

35. The method of claim 31 wherein the second coating layer is comprised of a mixture of hydroxypropyl methylcellulose and polyethylene glycol.

36. The method of claim 31 wherein the weight ratio of film forming polymer to anti-grit agent in the second coating layer is in the range of about 10:90 to about 90:10.

37. A texture masked particle comprising:
a) a core containing an active ingredient; and
b) a texture masking coating layer on the surface of the core, the texture masking coating layer comprised of
i) a film forming polymer; and
ii) an anti-grit agent.

38. The particle of claim 37, wherein the active ingredient is a nonsteroidal anti-inflammatory drug, acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, loperamide, ranitidine, cimetidine, astemizole, loratadine, desloratadine, fexofenadine, cetirizine, antacids, pharmaceutically acceptable salts thereof, metabolites thereof, and mixtures thereof.

39. The particle of claim 37 which meets the USP dissolution specification for immediate release dosage forms containing the particular active ingredient.

40. The particle of claim 37 wherein the film forming polymer is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and

001221-8425460

sodium carboxy methyl cellulose, starches, alginates, polyvinyl alcohols, xanthan gums, guar gums, polysaccharides, pectins, gelatins, and mixtures thereof.

41. The particle of claim 37 wherein the anti-grit agent is selected from the group consisting of polyethylene oxide, polyethylene glycol, and mixtures thereof.

42. The particle of claim 37 wherein the texture masking coating layer is comprised of a mixture of hydroxypropyl methylcellulose and polyethylene glycol.

43. The particle of claim 37 wherein the weight ratio of film forming polymer to anti-grit agent in the texture masking coating layer is in the range of about 10:90 to about 90:10.

44. The particle of claim 37 wherein the weight ratio of film forming polymer to anti-grit agent in the texture masking coating layer is in the range of about 50:50.

45. A tablet comprised of the particles of claim 37.

46. A chewable tablet comprised of the particles of claim 37.

47. The chewable tablet of claim 46, wherein the active ingredient is a nonsteroidal anti-inflammatory drug, acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, loperamide, ranitidine, cimetidine, astemizole, loratadine, desloratadine, fexofenadine, cetirizine, antacids, pharmaceutically acceptable salts thereof, metabolites thereof, and mixtures thereof.

48. The chewable tablet of claim 46 wherein the film forming polymer is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and sodium carboxy methyl cellulose, starches, alginates, polyvinyl alcohols, xanthan gums, guar gums, polysaccharides, pectins, gelatins, and mixtures thereof.

49. The chewable tablet of claim 46 wherein the anti-grit agent is selected from the group consisting of polyoxyethylene glycol, polyethylene glycol, and mixtures thereof.

50. The chewable tablet of claim 46 wherein the texture-masking coating layer is comprised of a mixture of hydroxypropyl methylcellulose and polyethylene glycol.

51. The chewable tablet of claim 46 wherein the weight ratio of film forming polymer to anti-grit agent in the texture-masking coating layer is in the range of about 10:90 to about 90:10.

001221-122100 745243-122100

52. A rapidly disintegrating tablet comprised of the particles of claim 37.

53. The rapidly disintegrating tablet of claim 52, wherein the active ingredient is a nonsteroidal anti-inflammatory drug, acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, loperamide, ranitidine, cimetidine, astemizole, loratadine, desloratadine, fexofenadine, cetirizine, antacids, pharmaceutically acceptable salts thereof, metabolites thereof, and mixtures thereof.

54. The rapidly disintegrating tablet of claim 52 wherein the film forming polymer is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and sodium carboxy methyl cellulose, starches, alginates, polyvinyl alcohols, xanthan gums, guar gums, polysaccharides, pectins, gelatins, and mixtures thereof.

55. The rapidly disintegrating tablet of claim 52 wherein the anti-grit agent is selected from the group consisting of polyoxyethylene glycol, polyethylene glycol, and mixtures thereof.

56. The rapidly disintegrating tablet of claim 52 wherein the texture masking coating layer is comprised of a mixture of hydroxypropyl methylcellulose and polyethylene glycol.

57. The rapidly disintegrating tablet of claim 52 wherein the weight ratio of film forming polymer to anti-grit agent in the texture masking coating layer is in the range of about 10:90 to about 90:10.

58. A method of texture masking particles comprising an active ingredient, which comprises:

a) applying a coating layer over the active ingredient, the coating layer comprising a mixture of 1) a film forming polymer; and 2) an anti-grit agent.

59. The method of claim 58, wherein the active ingredient is a nonsteroidal anti-inflammatory drug, acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, loperamide, ranitidine, cimetidine, astemizole, loratadine, desloratadine, fexofenadine, cetirizine, antacids, pharmaceutically acceptable salts thereof, metabolites thereof, and mixtures thereof.

60. The method of claim 58 wherein the film forming polymer is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and sodium carboxy methyl cellulose, starches, alginates, polyvinyl alcohols, xanthan gums, guar gums, polysaccharides, pectins, gelatins, and mixtures thereof.

61. The method of claim 58 wherein the anti-grit agent is selected from the group consisting of polyoxyethylene glycol, polyethylene glycol, and mixtures thereof.

5 62. The method of claim 58 wherein the coating layer is comprised of a mixture of hydroxypropyl methylcellulose and polyethylene glycol.

63. The method of claim 58 wherein the weight ratio of film forming polymer to anti-grit agent in the texture masking coating layer is in the range of about 10:90 to about 90:10.

10 64. The particle of claim 37 wherein the texture masking coating layer substantially covers the core.

65. A tablet comprising the particles of claim 64.

15 66. The method of claim 58 wherein the coating layer is substantially continuous.

67. A texture masked particle comprising a matrix, the matrix is comprised of:

- 20 a) an active ingredient;
b) a film forming polymer; and
c) an anti-grit agent,

wherein the film forming polymer and anti-grit agent are exposed at the surface of the particle in an amount effective for texture masking the active ingredient.

25 68. The particle of claim 67 wherein the average diameter of said particle is from about 50 to about 500 microns.

30 69. The particle of claim 67 wherein the weight ratio of film-forming polymer to anti-grit agent is from about 10:90 to about 90:10.

70. The particle of claim 67 wherein the film forming polymer and the anti-grit agent together are present in an amount, based on the weight of the texture masked particle, from about 25 to about 90%

35 71. The particle of claim 67 which is made by spray-drying a mixture comprising the active ingredient, a film forming polymer, and an anti-grit agent.

72. A method for making texture masked particles comprising an active ingredient, the method comprising spray-drying a mixture comprising

8A

- a) a film forming polymer and an anti-grit agent, which together are present in an amount effective for texture masking the active ingredient; and
- b) the active ingredient.

5

00745243.122100

MCP 231

20

ABSTRACT

Texture masked particles and chewable tablets made therefrom are disclosed. The texture masked particles are comprised of a core containing an active ingredient, an optional first coating layer comprised of a taste masking agent that substantially covers the core; and a second coating layer, which optionally may substantially cover the first coating layer or the core, comprised of a film forming polymer and a anti-grit agent. The particles may be produced into a tablet form, such as a chewable tablet form, that provides for the immediate release of the active ingredient.

10

Mcp231-4

001221-64254760

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Texture Masked Particles Containing an Active Ingredient, the specification of which

(check one) ☐ is attached hereto.

☒ was filed on December 21, 2000 as

Application Serial No. _____

and was amended on _____.
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

09745243.122100

87

Prior Foreign Application(s):

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119	
			☐ YES	☐ NO
			☐ YES	☐ NO
			☐ YES	☐ NO

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.

Filing Date

Status

Application Serial No.

Filing Date

Status

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith as well as to file equivalent patent applications in countries foreign to the United States including the filing of international patent applications in accordance with the Patent Cooperation Treaty:
Steven P. Berman (Reg. #24,772), Andrea L. Colby (Reg. #30,194), Paul A. Coletti (Reg. #32,019), Matthew S. Goodwin (Reg. #32,839), Ralph R. Palo (Reg. #29,486), Bernard F. Plantz (Reg. #32,091), Joseph F. Shirtz (Reg. #31,880), Michael Stark (Reg.

09745243-122100

#32,495), Mark R. Warfield (Reg. #33,463), and Michele G. Mangini (Reg. #36,806) One Johnson & Johnson Plaza, New Brunswick, NJ 08933.

Address all telephone calls to Michele G. Mangini at telephone no. (732) 524-2810.

Address all correspondence to Philip S. Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933-7003.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventor's Signature: _____

Full Name of Sole
or First Inventor

Narendra Parikh

Date: _____

Citizenship: USA

Residence: 14 Sycamore Lane, Long Valley, NJ 07853

Mailing Address: Same as above

Inventor's Signature: _____

Full Name of Second Joint
Inventor, If Any

Daniel McTeigue

Date: _____

Citizenship: USA

Residence: 106 N. Main St., N. Wales, PA 19454

Mailing Address: Same as above

Inventor's Signature: _____

Full Name of Fourth Joint
Inventor, If Any

David W. Wynn

Date: _____

Citizenship: USA

Residence: 1267 Huntington Road, Abington, PA 19001

Mailing Address: Same as above

09745243.122100

85

Inventor's Signature:
Full Name of Fifth Joint
Inventor, If Any

Ravivaj S. Pillai

Date: _____

Citizenship: India

Residence: 45 Lynwood Road, Landsdale, PA 19446

Mailing Address: Same as above

09745243.122100